Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States.

ABSTRACT:

Background

Current first-line treatments for metastatic renal cell carcinoma (mRCC) include the multityrosine kinase inhibitors pazopanib and sunitinib. Both agents had similar progression-free survival (PFS) and overall survival (OS) in the COMPARZ trial (Comparing the Efficacy, Safety and Tolerability of Pazopanib versus Sunitinib); however, the adverse event profiles of the 2 agents are different. In the PISCES trial (Patient Preference Study of Pazopanib versus Sunitinib in Advanced or Metastatic Kidney Cancer), patients and physicians preferred pazopanib primarily because it offered better health-related quality of life (HRQoL) and caused less fatigue.

Objective

To compare the cost-effectiveness of pazopanib versus sunitinib from a U.S. health care system perspective in

SUBMITTER: Delea TE 

PROVIDER: S-EPMC10397968 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature